Paul Matteis
Stock Analyst at Stifel
(1.34)
# 3,415
Out of 4,876 analysts
113
Total ratings
38.89%
Success rate
-12.83%
Average return
Main Sectors:
Stocks Rated by Paul Matteis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $78 → $94 | $62.76 | +49.78% | 2 | May 29, 2025 | |
| VIGL Vigil Neuroscience | Downgrades: Hold | $11 → $8 | $7.95 | +0.69% | 2 | May 28, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $300 → $345 | $322.83 | +6.87% | 14 | Mar 31, 2025 | |
| NMRA Neumora Therapeutics | Downgrades: Hold | $6 → $2 | $0.77 | +158.67% | 2 | Mar 7, 2025 | |
| SION Sionna Therapeutics | Initiates: Buy | $32 | $15.73 | +103.43% | 1 | Mar 4, 2025 | |
| GHRS GH Research | Maintains: Buy | $18 → $32 | $12.32 | +159.69% | 2 | Feb 27, 2025 | |
| CMPS COMPASS Pathways | Initiates: Buy | $11 | $2.78 | +295.68% | 1 | Feb 27, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Hold | $490 → $494 | $441.10 | +11.99% | 18 | Dec 16, 2024 | |
| QURE uniQure | Maintains: Buy | $12 → $32 | $13.84 | +131.30% | 1 | Dec 16, 2024 | |
| SAGE Sage Therapeutics | Maintains: Hold | $10 → $6 | $9.14 | -34.35% | 5 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $4 | $1.47 | +173.04% | 4 | Dec 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $10 | $2.35 | +325.53% | 3 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $44 → $60 | $16.21 | +270.14% | 2 | Nov 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $25 → $36 | $28.80 | +25.00% | 8 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $115 → $87 | $55.18 | +57.67% | 8 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $41 → $66 | $9.57 | +589.66% | 3 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $11.39 | +207.29% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $50 → $53 | $39.79 | +33.20% | 5 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $26 → $21 | $22.12 | -5.06% | 5 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $29 | $4.12 | +603.88% | 1 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $141 → $144 | $125.43 | +14.81% | 8 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $315 → $287 | $126.05 | +127.69% | 6 | Dec 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $4.11 | +387.21% | 1 | Nov 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $1.98 | +506.06% | 1 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $24 | $1.15 | +1,986.96% | 2 | Jun 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $36 → $5 | $0.31 | +1,538.27% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $54 → $32 | $11.40 | +180.70% | 1 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $1.15 | +2,247.83% | 1 | Jul 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.22 | +51.84% | 1 | Mar 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $64 | $6.66 | +861.68% | 1 | Feb 21, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $340 | $49.28 | +589.94% | 1 | Dec 21, 2016 |
Rhythm Pharmaceuticals
May 29, 2025
Maintains: Buy
Price Target: $78 → $94
Current: $62.76
Upside: +49.78%
Vigil Neuroscience
May 28, 2025
Downgrades: Hold
Price Target: $11 → $8
Current: $7.95
Upside: +0.69%
Alnylam Pharmaceuticals
Mar 31, 2025
Maintains: Buy
Price Target: $300 → $345
Current: $322.83
Upside: +6.87%
Neumora Therapeutics
Mar 7, 2025
Downgrades: Hold
Price Target: $6 → $2
Current: $0.77
Upside: +158.67%
Sionna Therapeutics
Mar 4, 2025
Initiates: Buy
Price Target: $32
Current: $15.73
Upside: +103.43%
GH Research
Feb 27, 2025
Maintains: Buy
Price Target: $18 → $32
Current: $12.32
Upside: +159.69%
COMPASS Pathways
Feb 27, 2025
Initiates: Buy
Price Target: $11
Current: $2.78
Upside: +295.68%
Vertex Pharmaceuticals
Dec 16, 2024
Maintains: Hold
Price Target: $490 → $494
Current: $441.10
Upside: +11.99%
uniQure
Dec 16, 2024
Maintains: Buy
Price Target: $12 → $32
Current: $13.84
Upside: +131.30%
Sage Therapeutics
Dec 16, 2024
Maintains: Hold
Price Target: $10 → $6
Current: $9.14
Upside: -34.35%
Dec 16, 2024
Downgrades: Hold
Price Target: $4
Current: $1.47
Upside: +173.04%
Nov 13, 2024
Maintains: Buy
Price Target: $32 → $10
Current: $2.35
Upside: +325.53%
Nov 12, 2024
Maintains: Buy
Price Target: $44 → $60
Current: $16.21
Upside: +270.14%
Nov 5, 2024
Upgrades: Buy
Price Target: $25 → $36
Current: $28.80
Upside: +25.00%
Sep 17, 2024
Maintains: Buy
Price Target: $115 → $87
Current: $55.18
Upside: +57.67%
Aug 16, 2024
Maintains: Buy
Price Target: $41 → $66
Current: $9.57
Upside: +589.66%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $11.39
Upside: +207.29%
Jun 27, 2024
Maintains: Hold
Price Target: $50 → $53
Current: $39.79
Upside: +33.20%
May 9, 2024
Maintains: Hold
Price Target: $26 → $21
Current: $22.12
Upside: -5.06%
Apr 30, 2024
Initiates: Buy
Price Target: $29
Current: $4.12
Upside: +603.88%
Dec 18, 2023
Maintains: Buy
Price Target: $141 → $144
Current: $125.43
Upside: +14.81%
Dec 14, 2023
Maintains: Buy
Price Target: $315 → $287
Current: $126.05
Upside: +127.69%
Nov 28, 2023
Initiates: Buy
Price Target: $20
Current: $4.11
Upside: +387.21%
Nov 14, 2023
Initiates: Buy
Price Target: $12
Current: $1.98
Upside: +506.06%
Jun 14, 2023
Reiterates: Buy
Price Target: $24
Current: $1.15
Upside: +1,986.96%
Jun 23, 2022
Downgrades: Hold
Price Target: $36 → $5
Current: $0.31
Upside: +1,538.27%
Jun 8, 2022
Maintains: Buy
Price Target: $54 → $32
Current: $11.40
Upside: +180.70%
Jul 26, 2021
Initiates: Buy
Price Target: $27
Current: $1.15
Upside: +2,247.83%
Mar 12, 2020
Initiates: Buy
Price Target: $14
Current: $9.22
Upside: +51.84%
Feb 21, 2018
Maintains: Outperform
Price Target: $53 → $64
Current: $6.66
Upside: +861.68%
Dec 21, 2016
Initiates: Outperform
Price Target: $340
Current: $49.28
Upside: +589.94%